Thrombolytic agents in district hospitals

Eastern Mediterranean Health Journal

Volumn 5, Issue 1, 1999, Pages 182-185

  Sara, K ^a  

^a WHO Regional Office for the Eastern Mediterranean   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

DEVELOPING COUNTRY; DRUG UTILIZATION; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; PRACTICE GUIDELINE; PUBLIC HOSPITAL; REVIEW; TIME; TREATMENT OUTCOME;

DEVELOPING COUNTRIES; DRUG UTILIZATION; FIBRINOLYTIC AGENTS; HOSPITALS, DISTRICT; HUMANS; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; QUALITY ASSURANCE, HEALTH CARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032600628     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Alwan A, ed. Prevention and control of cardiovascular diseases. Alexandria, Egypt, World Health Organization Regional Office for the Eastern Mediterranean, 1995 (unpublished document WHO-EM/CVD/27, available on request from Non-Communicable Diseases Unit, WHO/EMRO).
2. Alwan A. Cardiovascular diseases in the Eastern Mediterranean Region. World health statistics quarterly, 1993, 46:97-100.
3. Prevention in childhood and youth of adult cardiovascular diseases: time for action. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No. 792).
4. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. NIH Consensus Conference. Triglyceride, high-density lipoprotein, and coronary heart disease. Journal of the American Medical Association, 1993, 269(4):505-10.
5. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Journal of the American Medical Association, 1993, 269(23):3015-23.
6. Gomez-Marin O et al. Improvement in long-term survival among patients hospitalized with acute myocardial infarction, 1970 to 1980. The Minnesota Heart Survey. New England journal of medicine, 1987, 316(22):1353-9.
7. Rennie J. [There is a treatment for heart attack that is neglected to a dangerous extent]. Scientific American (Arabic issue) 12(3), March 1996.
8. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New England journal of medicine, 1993, 329(10):673-82.
9. Lee KL et al. Predictors of 30 day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41 021 patients. GUSTO investigators. Circulation, 1995, 91 (6):1659-68.
10. Mueller HS et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation, 1992, 85(4):1254-64.
11. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet, 1994, 343(8893):311-22.
12. Marder VJ, Sherry S. Thrombolytic therapy: current status. New England journal of medicine, 1988, 318(23): 1512-20;
13. Marder VJ, Sherry S. New England journal of medicine, 318(24):1585-95.
14. Weaver WD et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. Journal of the American Medical Association, 1996, 275(10):777-82.
15. TIMI Study Group. The thrombolysis in myocardial infarction. New England journal of medicine, 1985, 312(14):932-6.
16. Sheehan FH et al. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI phase I) trial. Circulation, 1987, 75(4):817-29.
17. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarcto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet, 1987, 2(8564):871-4.
18. The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). Mortality, morbidity and infarct size at 21 days. New England journal of medicine, 1986, 314(23):1465-71.
19. Maggioni AP et al. For the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico II (GISSI-2) and the International Study Group. The risk of stroke in patients with acute myocardial infarction after thrombolytic and anti- thrombolytic treatment. New England journal of medicine, 1992, 327(1):1-6.
20. Mathey DG et al. Time from onset of symptoms to thrombolytic therapy: a major determinant of myocardial salvage in patients with acute transmural infarction. Journal of the American College of Cardiology, 1985, 6(3):518-25.
21. Weaver WD for the National Registry of Myocardial Infarction Investigators. Factors influencing the time to hospital administration of thrombolytic therapy: result from a large national registry. Circulation, 1992, 86(1):1-16.